Isolated hepatic perfusion for unresectable hepatic malignancies: A systematic review and meta-analysis

Table 5 Long-term survival outcomes after isolated hepatic perfusion

Ref.	Median follow-up (mo)	Median time to local progression (mo)	Median time to systemic progression (mo)	Median hepatic progression-free survival (mo)	Overall survival
					Median OS (mo from IHP)	1-yr survival (%)	2-yr survival (%)	3-yr survival (%)	4-yr survival (%)	5-yr survival (%)
Olofsson et al[55]	NR	7 (0-31)	13 (2-34)	NR	24	NR	NR	NR	NR	NR
Magge et al[56]	NR	NR	NR	For CRC group: 12 (10.53-13.47) For CR: 12 For PR: 12 (10.1-13.9) For SD: 12.5 (10.53-13.47)	23 (15-28)	NR	NR	NR	NR	NR
Fukumoto et al[57]	20 (3-191)	NR	NR	NR	25	80.6%	NR	35.7%	NR	27.6%
Alexander et al[58]	78.1 (52.1-104.2)	7.3 (6.5-8.0)		NR	25 (19.4-30.6)	NR	53%	28%	14%	NR
van Iersel et al[59]	NR	NR	NR	7	17.4	NR	34%	NR	NR	NR
Rizell et al[60]	IHP I cohort: NR IHP II cohort: NR IHP III cohort: 7 (range 4-18)	NR	NR	NR	12.6 (2.5-57)	NR	NR	NR	NR	NR
Alexander et al[62]	11 (3-40)	8		12	12.1 (3-39+)	NR	NR	NR	NR	NR
Median value (range)					20 (12.1-25)

OS: Overall survival; NR: Not reported; CRC: Colorectal cancer; CR: Complete response; PR: Partial response; SD: Stable disease.